The Oncology Institute, Inc. (STLN) — Tangible Net Worth Ratio
The Oncology Institute, Inc. (STLN) has a Tangible Net Worth Ratio of -176.9% as of March 2025. This metric is calculated by deducting intangible assets ($14.04 Million) from net assets ($5.07 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore STLN year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
The Oncology Institute, Inc. Tangible Net Worth Ratio (2022–2024)
This chart shows how The Oncology Institute, Inc.'s Tangible Net Worth Ratio has changed across 3 annual periods from 2022 to 2024. As of March 2025, the ratio stands at -176.9%, reflecting net assets of $5.07 Million with intangible assets of $14.04 Million USD. Check how strategically is The Oncology Institute, Inc.'s equity deployed to assess the company's strategic physical and investment asset allocation.
Annual Tangible Net Worth Ratio for The Oncology Institute, Inc. (2022–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for The Oncology Institute, Inc. from 2022 to 2024, covering 3 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see STLN market cap.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | -312.6% | $3.59 Million | $14.81 Million | $172.72 Million | ▼ -381.3 pp |
| 2023 | 68.6% | $57.02 Million | $17.90 Million | $209.24 Million | ▼ -16.8 pp |
| 2022 | 85.4% | $123.17 Million | $17.96 Million | $261.67 Million | — |